JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koch, N.
Right arrow Articles by Tamalet, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koch, N.
Right arrow Articles by Tamalet, C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 1999, p. 1595-1597, Vol. 37, No. 5
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Comparison of Human Immunodeficiency Virus Type 1 (HIV-1) Protease Mutations in HIV-1 Genomes Detected in Plasma and in Peripheral Blood Mononuclear Cells from Patients Receiving Combination Drug Therapy

Nathalie Koch,1 Nouara Yahi,1 Franck Ariasi,2 Jacques Fantini,2 and Catherine Tamalet1,*

Laboratoire de Virologie, CHRU La Timone, 13005 Marseille,1 and Laboratoire de Biochimie et Biologie de la Nutrition, CNRS ESA 6033, Faculté des Sciences St. Jérôme, 13013 Marseille,2 France

Received 4 May 1998/Returned for modification 17 August 1998/Accepted 1 February 1999

Detections of mutations in the protease gene of human immunodeficiency virus type 1 in plasma and peripheral blood mononuclear cells (PBMC) were sought in two matched populations of 23 individuals receiving combination drug therapy with or without protease inhibitors. In the control group (23 patients not receiving protease inhibitors), no primary resistance mutations were found. In contrast, primary resistance mutations (especially at codons M46, V82, and L90) were found in 16 of 23 patients (70%) treated with protease inhibitors. In 30% of the cases, these mutations were detected in plasma but not in PBMC.

* Corresponding author. Mailing address: Laboratoire de Virologie, CHRU La Timone, 13005 Marseille, France. Phone: 33-491-385-522. Fax: 33-491-779-266. E-mail: ctamalet{at}ap-hm.fr.

Journal of Clinical Microbiology, May 1999, p. 1595-1597, Vol. 37, No. 5
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.